Compare SPCE & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | BWAY |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | SPCE | BWAY |
|---|---|---|
| Price | $3.29 | $19.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $9.22 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 6.0M | 65.1K |
| Earning Date | 11-13-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | $1,661,000.00 | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | $2,656.89 | $22.24 |
| P/E Ratio | ★ N/A | $60.34 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $2.18 | $7.84 |
| 52 Week High | $6.74 | $19.80 |
| Indicator | SPCE | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 63.45 |
| Support Level | $3.15 | $18.62 |
| Resistance Level | $3.33 | $19.61 |
| Average True Range (ATR) | 0.27 | 0.85 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 33.04 | 83.16 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.